Figure 1From: Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F Summary of blood counts, molecular analyses and cytoreductive therapy in a patient with a CML with JAK2V617F clonal evolution under treatment with imatinib and dasatinib. Back to article page